Rusfertide: "VERIFY study met its primary endpoint during weeks 20-32 (Part 1a)"; Polycythemia vera (Protagonist Therapeutics) - Jun 2, 2025 - ASCO 2025: "Significantly reduced the mean number of PHL and improved Hct control in the desired target range (Hct < 45%) vs. placebo"
P3 data • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|